MARKET

AUTL

AUTL

AUTOLUS THERAPEUTICS PLC
NASDAQ
1.420
+0.100
+7.58%
After Hours: 1.408 -0.012 -0.82% 19:59 02/06 EST
OPEN
1.340
PREV CLOSE
1.320
HIGH
1.430
LOW
1.330
VOLUME
1.18M
TURNOVER
--
52 WEEK HIGH
2.700
52 WEEK LOW
1.105
MARKET CAP
377.92M
P/E (TTM)
-1.6813
1D
5D
1M
3M
1Y
5Y
1D
Autolus Therapeutics reports inducement grants under Nasdaq listing rule
TipRanks · 4d ago
The Market Doesn't Like What It Sees From Autolus Therapeutics plc's (NASDAQ:AUTL) Revenues Yet As Shares Tumble 26%
Simply Wall St · 5d ago
Weekly Report: what happened at AUTL last week (0126-0130)?
Weekly Report · 6d ago
Autolus Therapeutics Signs Long-Term Lentiviral Supply Agreement
TipRanks · 01/26 21:32
Autolus Therapeutics' Subsidiary Signs Agreement With AGC Biologics To Manufacture, Supply Lentiviral Vector
Benzinga · 01/26 21:14
Weekly Report: what happened at AUTL last week (0119-0123)?
Weekly Report · 01/26 09:46
3 Promising Penny Stocks With Market Caps Over $70M
Simply Wall St · 01/21 11:05
Weekly Report: what happened at AUTL last week (0112-0116)?
Weekly Report · 01/19 09:49
More
About AUTL
Autolus Therapeutics plc is a United Kingdom-based early commercial-stage biopharmaceutical company developing programmed T cell therapies for the treatment of cancer and autoimmune diseases. The Company has an approved commercial product, AUCATZYL, for the treatment of adult patients with r/r B-ALL. Using a suite of proprietary and modular T cell programming technologies, it is also developing five programs in seven hematological and solid tumor indications and one autoimmune indication. It is engineering precisely targeted, controlled and highly active T cell therapies that are designed to better recognize target cells, break down their defense mechanisms and attack and eliminate these cells. Its product pipeline includes obe-cel (ALLCAR19), obe-cel (CAROUSEL), AUTO1/22 (CARPALL), AUTO4 (LibrA T1), AUTO6 (MAGNETO), AUTO5, AUTO8 (MCARTY) and AUTO9. AUTO4 and AUTO5 are two programmed T cell therapies for the treatment of peripheral T-cell lymphoma targeting TRBC 1 and TRBC 2.

Webull offers Autolus Therapeutics PLC (ADR) stock information, including NASDAQ: AUTL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AUTL stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AUTL stock methods without spending real money on the virtual paper trading platform.